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Binding to plasma proteins, playing a pivotal
role in distribution, elimination and therapeutic
effectiveness of drugs, has long been considered as
one of their most important physicochemical char-
acteristics. This is because only free (unbound) drug
can pass through cell membranes and reach the tar-
get site in the body such as an appropriate receptor,
transporter or enzyme. Moreover, a knowledge of
drugs protein binding properties has become an
important issue for understanding pharmacokineti-
cally relevant binding phenomena such as displace-
ment reaction between different drugs or the signif-
icant alteration of plasma protein binding of some
drugs during certain pathophysiological states (1).
For these reasons, the plasma protein binding
parameters should be estimated at the early stage of
drug discovery as one of the selection criterion for
new drug candidates (2). 
Compound 1-[3-(4-tert-butyl-phenoxy)prop-
yl]piperidine (DL76) is an example of new non-imi-
dazole histamine H3 antagonist. In preliminary phar-
macological studies it shows good affinity for H3
receptors (hKi equal 22 ± 3 nM; iodoproxyfan bind-
ing assay at human H3 receptor stably expressed in
CHO-K1 cells) and ED50 equals 2.8 ± 0.4 mg/kg
(central histamine H3 receptor assay in vivo after p.o.
administration to mice) (3).
Blockade of the H3 autoreceptors by antago-
nists interrupts the negative feedback mechanism
and leads to increased levels of histamine and other
neurotransmitters. These effects suggest a potential
therapeutic role of H3 receptor antagonists in the
treatment of several diseases and neurological disor-
ders, such as schizophrenia, depression, sleep-wake
disorders, dementia or epilepsy (4). A lack of the
imidazole moiety in the structure of DL76 may
improve its pharmacokinetic profile and increase
safety of administration comparing to the imidazole
H3 antagonist (5). 
Although there are many plasma components
capable of binding drugs (e.g., acid α1-glycoprotein,
lipoproteins, globulins, erythrocytes), albumin is
present in the highest quantities and is able to bind
to a broad variety of drugs with an affinity sufficient
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to have a significant effect on their pharmacokinetic
profile and action (6, 7).
The aim of this study was to evaluate the bind-
ing rate of DL76 to bovine serum albumin and to
determine its binding parameters such as number of




as a monobasic oxalate was supplied from The
Department of Technology and Biotechnology of
Drugs (Faculty of Pharmacy, Jagiellonian
University Medical College, KrakÛw, Poland).
Pentoxifylline (3,7-dimethyl-1-(5-oxohexyl)-3,7-
dihydro-1H-purine-2,6-dione, PTX), used as an
internal standard and bovine serum albumin (BSA)
BioChemika (fraction V, = 96%) were obtained
from Sigma Aldrich (St. Louis, MO, USA) and a
molecular weight of 66430 g/mol for the BSA was
assumed. HPLC grade acetonitrile, water, formic
acid and ethyl acetate were purchased from Merck
(Darmstadt, Germany). The phosphate buffer solu-
tion 0.067 M (PBS) was adjusted to the desired pH
(7.4 ± 0.05) by an addition of hydrochloric acid or
sodium hydroxide. 
DL76 concentration assay 
The quantitative measurement of DL76 in
albumin and buffer solution was made by validated
LC/MS/MS method, according to the procedure
described previously (8). The method was adopted
to the modified matrices. LC/MS/MS system con-
sisted of high performance liquid chromatograph
Agilent 1100 (Agilent Technologies, Waldbronn,
Germany) and triple quadrupole mass spectrometer
API 2000 (Applied Biosystems MDX Sciex,
Concorde, Ontario, Canada) equipped with an elec-
trospray ionization interface (ESI). ESI ionization
was performed in the positive ion mode. The mass
spectrometer was operated in selected reactions
monitoring mode (SRM) monitoring the transition
of the protonated molecular ions m/z 276 to 98 for
DL76 and 279 to 181 for internal standard (PTX).
Chromatographic separation was carried out with a
XBridgeôC18 (2.1 ◊ 30 mm, 3.5 µm, Waters,
Ireland) analytical column. The mobile phase con-
sisted of acetonitrile/water (v/v) with an addition of
0.1% of formic acid, was set at the flow rate of 300
µL/min and the gradient elution was used. A 100 µL
aliquot of phosphate buffered saline containing BSA
and unknown concentration of DL76 was briefly
mixed with the 10 µL of IS and then 1 mL of ethyl
acetate was added. The mixture was shaken on a
mechanical shaker for 20 min and centrifuged at
3,000 rpm for 15 min. The organic layer (0.5 mL)
was transferred into conical tubes and evaporated to
dryness at 37OC under the stream of nitrogen gas in
the TurboVap evaporator (Zymark, Hopkinton, MA,
USA). The dry residue was reconstituted with 100
µL of acetonitrile/water (50/50, v/v) and aliquot of
10 µL was injected onto the LC/MS/MS system.
Extraction recovery of DL76 from buffered protein
solutions was high (100%). The limit of detection in
the SRM mode was found to be 18.15 nM and the
limit of quantification was 36.3 nM. The precision
and accuracy for both intra- and inter-day determi-
nation of DL76 ranged from 1.65 to 15.09% and
from 88.74 to 113.43%, respectively. The linear
detection response was observed in the range 36.3
nM ñ 7.27 µM and therefore, the samples with
expected higher concentrations were diluted. The
concentration of DL76 in the PBS was measured by
direct injection into an analytical system without
prior purification of the sample.
Binding study
The binding of DL76 to BSA was determined
by equilibrium dialysis method using Fast Micro-
Equilibrium Dialyzer consisting of two chambers
with compartment volume of 500 µL each, separat-
ed by semi permeable regenerated cellulose dialysis
membrane with a molecular weight cut-off of
10,000 Da (Harvard Apparatus, Holliston, MA,
USA). One chamber contained various initial con-
centrations of DL76 (range 0.32ñ317.18 mM) dis-
solved in isotonic phosphate buffer (pH 7.4) and the
other buffered isotonic solution of physiological
concentration of BSA (602 µM). The dialysis was
performed for 3 h (time to equilibrium ) at 37OC
under a constant stirring at 100 rpm. After comple-
tion of dialysis, the concentrations of DL76 were
measured in both chambers using analytical method
described above. Time to achieve the equilibrium
state was determined experimentally during prelim-
inary studies by analyzing the concentration of
DL76 in both chambers of the dialyzer (DL76 in
buffer against BSA in buffer) at increasing time
periods. When no change in the concentration of
DL76 in both chambers was detected between sev-
eral time points, an equilibrium state was assumed
to be reached. Assays were repeated three to five
times, and the average values of concentrations were
used to calculate binding data. 
In order to eliminate some of the possible
experimental errors, drug stability and its adsorption
to the dialysis system were tested. The stability of
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DL76 was tested for 6 h at temperature of 37OC at
the low (0.79 µM) and high (237 µM) concentra-
tions. The study was based on the determination of
the concentration of DL76 in the freshly prepared
samples and after 6 h of incubation at 37OC. The sta-
bility was expressed as a percentage ratio of the con-
centrations of incubated sample/freshly prepared
sample. The DL76 was considered to be stable if
less than 5% difference in concentration was
observed. The possibility of adsorption of the inves-
tigated compound to the dialysis system and mem-
brane was determined by comparing the amount of
DL76 added to one chamber before dialysis to the
one calculated based on the concentrations meas-
ured post-dialysis (buffer with DL76 against buffer)
on both sides of the dialysis membrane .
Data analysis
The fraction of DL76 bound to BSA (fb) was
determined by the following equation:
fb = (Ct ñ Cu)/Ct (1)
where Ct = total concentration of drug in the albu-
min solution at equilibrium and Cu = unbound drug
concentration in the chamber without albumin at
equilibrium.
The bound drug concentration was calculated
using a formula:
Cb = Ct ñ Cu (2)
Binding parameters were determined by non-
linear regression method using Wolfram
Mathematica 7 to fit the data to equation: 





where r = number of moles of drug bound per mole
of protein (Cb/Pt; Pt is a total protein concentration);
m = number of independent classes of binding sites;
Kdi = dissociation constant for the i-th class and ni =
number of binding sites in the i-th class.
In the regression analysis several factors were
taken into consideration such as possible presence of
one or two classes of binding sites as well as non-
specific binding (NSB). The final model used for
description of albumin binding characteristics of
DL76 was selected based on goodness-of-fit criteria
such as Akaike Information Criterion (AIC) value.
The binding data of DL76 were also analyzed
using Scatchard transformation where a curve was
produced by plotting r/Cu versus r. 
RESULTS AND DISCUSSION
DL76 is a new compound, therefore, its protein
binding parameters have not been reported previ-
ously. To evaluate the binding characteristics of this
compound to the main plasma protein i.e., albumin,
the equilibrium dialysis method was used. This
method is considered to be the reference method
from among all the other techniques used for the
determination of protein binding (9). Time to reach
the equilibrium state is one of the most important
variables in the equilibrium dialysis and in this
experiment it was quite short and equals 3 h at the
Figure 1. Binding plot of mean (n = 3ñ5) bound (Cb) versus mean free (Cu) concentration values of DL76 to bovine serum albumin (phys-
iological concentration of 602 µM) estimated at 37OC by equilibrium dialysis technique. The experiment was carried out over the DL76
concentration range of 0.32ñ317.18 µM at pH 7.4
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temperature of 37OC. DL76 was determined to be
stable during the whole experiment and its adsorp-
tion to the dialysis system was below 3%.
The binding plot of DL76 to BSA (602 µM) is
presented in Figure 1. The plot was obtained by sub-
sequent iterations using one class of binding sites
with or without nonspecific binding site or two
classes of binding sites. The AIC values for these
three models of DL76 albumin binding were ñ70.66;
ñ68.66 and ñ66.66, respectively. The lowest value
of AIC indicates the best fitting of data to the one
class of binding sites (m = 1) with Kd value equal
49.20 µM and n equal 0.459.
The binding association constant of DL76 (Ka)
with BSA being a reciprocal of Kd equals 2.03 ◊∑104
M-1. It was found that the highest percentage of albu-
Figure 2. Scatchard plot for binding of DL76 to BSA (602 µM). The results are the mean of 3ñ5 measurements. The concave downwards
curve is characteristic of positive cooperativity binding. Abbreviations and symbols: Cu ñ unbound compound concentration, Cb ñ bound
compound concentration 
Figure 3. Hill plot for binding between DL76 and BSA. A value of Hill coefficient (slope) above 1 indicates the presence of positive coop-
erativity in the binding of DL76 to BSA. Abbreviations and symbols: Cu ñ unbound compound concentration, Cb ñ bound compound con-
centration, Pt ñ protein concentration (602 µM)
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min protein binding of DL76 near the saturation
level calculated from the equation (1) was about
80%. These data may indicate that DL76 with its
physicochemical characteristics (basic with pKa =
9.15 and lipophilic with logP = 4.97) belongs to the
group of compounds that highly bind to the BSA
with moderate affinity in a typical range of 02ñ104
M-1 (10).
The results of Scatchard analysis of the bind-
ing data are presented in Figure 2. A concave-
down curve may indicate the presence of positive
cooperativity, which takes place when the binding
of a ligand at one site increases the affinity of a
separate ligand molecules for binding at another
site (11). One the mechanisms of this phenomenon
may be an allosteric communication between
binding sites (12).
One of the methods used for the differentiation
of cooperativity (positive or negative) is the Hill
slope analysis presented in Figure 3. The Hill curve
was produced by plotting ln (Cb/(Pt ñ Cb)) versus ln
Cu. A value of Hill coefficient above 1 confirms the
presence of positive cooperativity (13). This coeffi-
cient also expresses the average number of interact-
ing sites. In presented study, value of the Hill slope
was determined to be 1.19, which verifies the posi-
tive cooperativity and, in addition, indicates the
existence of two binding sites interacting in the
process of binding DL76 to BSA. 
The classic example of positive cooperativity
is oxygen binding to hemoglobin (14). This kind of
reciprocal action was proven to exist also in other
biological systems. It is suggested in the estrogen
receptor α-estradiol interaction at high level of
receptor concentration or for interaction of γ-
hydroxybutyric acid with the membrane of rat brain
(15, 16). Moreover, positive and negative coopera-
tivity was found in an analysis of binding of nicotin-
amide-adenine dinucleotide to yeast glyceralde-
hyde-3-phosphate dehydrogenase (17).
Based on these examples is can be concluded
that phenomenon of positive cooperativity may play
an important role not only in the plasma protein
binding of different compounds but also in their
interaction with other proteins e.g., receptors and
enzymes. 
CONCLUSIONS
The presented study reports the plasma albu-
min binding characteristics of DL76 compound.
From the obtained data it can be concluded that
investigated compound binds to the plasma albumin
in approximately 80%, and that there is a positive
cooperativity (Hill slope above 1) in the binding
process between DL76 and BSA. Using non linear
regression analysis, the lowest value of AIC indi-
cates the best fitting of data to the one class of bind-
ing sites (m = 1) with moderate protein binding of
DL76 (Kd value equal 49.20 µM and n equal 0.459).
The received results give an important infor-
mation about DL76 compound and can help in the
interpretation of some pharmacological and pharma-
cokinetic data. They also may be a source of useful
information for scientists seeking new compounds
in this chemical group. 
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